Shanghai, China—D3 Bio (Wuxi) Co. Ltd (“D3 Bio” or “The Company”), a biotechnology company that focuses on discovery, development, and registration of innovative medicines in the fields of oncology and immune-oncology, announces the following regulatory approvals and pipeline data presentation:
The two presentations are:
Session Category: Clinical Research Excluding Trials
Session Title: Combination Therapies for Cancer
Session Date and Time: Tuesday Apr 18, 2023, 1:30 PM - 5:00 PM
Location: Poster Section 38
Poster Board Number: 19
Published Abstract Number: 5501
Session Category: Immunology
Session Title: Therapeutic Antibodies 1
Session Date and Time: Monday Apr 17, 2023, 9:00 AM - 12:30 PM
Location: Poster Section 25
Poster Board Number: 12
Published Abstract Number: 1873
For more information about D3 Bio at AACR 2023, please go to https://www.aacr.org/meeting/aacr-annual-meeting-2023/
D3S-001 is a selective and covalent KRAS G12C small molecule inhibitor designed to enhance KRAS G12C target engagement. In preclinical investigation, D3S-001 has demonstrated high potency, CNS penetration property and capability to achieve complete KRAS G12C target engagement at predicted clinically relevant dose. It is currently in global phase 1 development as an oral therapeutic agent for the treatment of patients with advanced solid tumors harboring KRAS G12C mutation, including Non-Small Cell Lung Cancer (NSCLC), CRC and Pancreatic cancer. For detailed information about D3S-001, please refer to our recent publication at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
D3S-002 is a small molecule kinase inhibitor of ERK1/2 that demonstrated promising activity, selectivity, and favorable safety profiles in preclinical assessment. D3S-002 has received FDA’s IND clearance and its FIH study will be initiated soon.
D3L-001 is a novel HER2×CD47 bi-specific antibody (bsAb), which demonstrated potent and synergistic anti-tumor effect via HER2 guided CD47 co-blocking in both in vitro and in vivo models. D3L-001 has received FDA’s IND clearance and its FIH study will be initiated soon.
D3 Bio is a globally orientated, clinical stage biotechnology company that focuses on the discovery, development, and registration of new medicines in oncology and immunology. At D3 Bio, we fully leverage our clinical insight and biomarker strategy to guide our discovery effort and compound development, aiming to create novel and clinically meaningful new therapies for patients in need.
D3 Bio is funded by globally renowned investors, including Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek, and WuXi AppTec's Corporate Venture Fund.
For inquiries, please contact: